A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
about
Nintedanib in NSCLC: evidence to date and place in therapyIdiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanibProfile of nintedanib in the treatment of solid tumors: the evidence to dateTargeting angiogenesis in squamous non-small cell lung cancerEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibNonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRA randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanibFocus on Nintedanib in NSCLC and Other TumorsSecond-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib.BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.Nintedanib for the treatment of non-small-cell lung cancer.Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.Nintedanib in non-small cell lung cancer: from preclinical to approval.Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.Targeting FGFR in Squamous Cell Carcinoma of the Lung.Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence.RAS interaction with PI3K p110α is required for tumor-induced angiogenesis.A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.Nintedanib in ovarian cancer.Newly developed anti-angiogenic therapy in non-small cell lung cancer.
P2860
Q26745424-283C725F-6CDF-4A3A-9EFA-6566E6B4A180Q26771647-4725AEC4-BC96-43FE-83D4-EA8AE3DD357AQ26775134-8AF2CC58-25BD-4CA5-8656-7750D984F36FQ26861341-4A05C97A-F937-409E-8606-746309C3AF62Q26995204-687B0C09-3653-44D8-858A-7D077B460379Q27693185-EF62DA79-F43F-4CA5-A2B0-F2160F1BCBA6Q28086993-0C2FB622-DA78-490B-847B-E7BE457BA371Q36287386-6AF266EB-A249-4729-AF90-38A3B48A4AEDQ36750974-B034FFD2-B9E4-42AF-8532-B57B49AF7F5BQ36927086-12A832F0-C38D-4C7D-BA86-DDD129E2A06BQ36957621-11113D7F-E986-4580-B68B-41AAA6DB4430Q37512962-9CBF4EE8-9B01-4A81-9FEA-2C993314914EQ37670497-C843E8DB-7180-422B-9EEE-94889CBE4D9FQ38116094-5E5459C3-F8FD-456C-B662-BB8AC4FF58D0Q38153445-E592D5AA-939F-4020-BBFC-405C559E8367Q38193571-595E2CA2-FBFB-4E09-8E3D-28EB32A6C948Q38221689-8B5BCBD9-8CA7-4B4A-A781-C19CBA3D223DQ38239545-E16F1910-C89C-427F-A3A6-79CAE87A2F00Q38286128-9179A72B-B081-4CDD-A70A-6CEACBBF3107Q38412048-44AB1217-02D7-42DA-B15C-2E96D6981118Q38430583-DD3065CB-63BD-4A32-9920-CA18F8B29DC6Q38498207-0C1CBC62-6C14-4D7C-9BD1-DE315598E7D2Q38552883-B5DCC053-FB85-40EF-B4CD-489B5C033077Q38690050-6C3CA4A9-9217-4CD0-AE65-1116833E0C6DQ38956300-838DAEE2-0B0F-44DA-9B0A-C33A5FA48731Q38977239-8CBD8079-BA57-4688-A6C0-871A7FC397B6Q39008385-B7E37BE5-03E1-46C2-8ED5-F010D927AE06Q41130079-1E937176-26FD-4151-98E4-0A5672692268Q42738385-E9D93EB3-8420-4E70-9A13-2EBC88E58E85Q47719824-3A697E4B-8C7D-4127-8D4C-E45269A5EE0DQ51824301-BE3EE2FD-DB21-47E3-8248-B8D2F78E9F9FQ52668159-7E55D63D-1F52-4F09-B2EA-D1D159881FEF
P2860
A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase I, open-label dose-esc ...... ed non-small-cell lung cancer.
@ast
A phase I, open-label dose-esc ...... ed non-small-cell lung cancer.
@en
type
label
A phase I, open-label dose-esc ...... ed non-small-cell lung cancer.
@ast
A phase I, open-label dose-esc ...... ed non-small-cell lung cancer.
@en
prefLabel
A phase I, open-label dose-esc ...... ed non-small-cell lung cancer.
@ast
A phase I, open-label dose-esc ...... ed non-small-cell lung cancer.
@en
P2093
P2860
P356
P1433
P1476
A phase I, open-label dose-esc ...... ed non-small-cell lung cancer.
@en
P2093
A M Traynor
D R Camidge
G A Otterson
P Conkling
R C Doebele
P2860
P304
P356
10.1093/ANNONC/MDR596
P577
2012-02-16T00:00:00Z